Shares of Health Care sector company Zoetis moved -3.8% today, and are now trading at a price of $155.6. The Large-Cap stock's daily volume was 2,904,412 compared to its average volume of 2,873,706. The S&P 500 index returned a -0.0% performance.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company is based in Parsippany and has 13,800 full time employees. Its market capitalization is $69,274,370,048. Zoetis currently offers its equity investors a dividend that yields 1.1% per year.
15 analysts are following Zoetis and have set target prices ranging from $165.0 to $238.0 per share. On average, they have given the company a rating of buy. At today's prices, ZTS is trading -20.36% away from its average analyst target price of $195.37 per share.
Over the last year, ZTS shares have gone down by -3.9%, which represents a difference of -13.2% when compared to the S&P 500. The stock's 52 week high is $200.33 per share and its 52 week low is $139.7. With average free cash flows of $1.66 Billion that have been growing at an average rate of 8.8% over the last 5 years, Zoetis declining stock performance may not be reflective of the quality of its underlying business.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 2,953,000 | 655,000 | 2,298,000 | 41.76 |
| 2023 | 2,353,000 | 732,000 | 1,621,000 | 22.25 |
| 2022 | 1,912,000 | 586,000 | 1,326,000 | -23.62 |
| 2021 | 2,213,000 | 477,000 | 1,736,000 | 3.77 |
| 2020 | 2,126,000 | 453,000 | 1,673,000 | 25.32 |
| 2019 | 1,795,000 | 460,000 | 1,335,000 |
